YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - Smooth Rock Ventures Corp. (TSXV: SMRV) (OTC Pink: SMRVF) (the "Company") announces that, further to its news release dated September 10, 2026, it will be changing its na…
Perspective Therapeutics, Inc. SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering adv…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Perspective Therapeutics (CATX) is a stock that can certainly grab the attention of many investors, but…
The second-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector is pretty good so far. The sector primarily comprises pharma/biotech and medical device companies. The earnings season for the pharma/…
European orphan medicinal product designation granted for [²¹²Pb]VMT-α-NET for the treatment of GEP-NETs[²¹²Pb]VMT-α-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive neuroendocrine tumors; interim clini…
SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers thr…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Perspective Therapeutics (CATX) is a stock that can certainly grab the attention of many investors, but…
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers thr…
Perspective Therapeutics, Inc. Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics…
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, now stretching into a new brain tumor in…
SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers thr…
One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in la…
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers thro…
Avidity Partners Management disclosed a buy of 259,700 shares of Enliven Therapeutics(NASDAQ:ELVN) in its May 13, 2026, SEC filing, an estimated $7.19 million transaction based on quarterly average pricing. What happened According to a SEC…
Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 milli…
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million based on quarterly average pricing. What…
(RTTNews) - Wedbush analyst David Nierengarten on Monday reiterated an Outperform rating and a 12-month price target of $11 for Perspective Therapeutics, Inc. (CATX), a clinical-stage radiopharmaceutical company. Perspective develops preci…
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, to…
Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on tra…
* Perspective Therapeutics (CATX [https://seekingalpha.com/symbol/CATX]) is scheduled to announce Q4 earnings results on Monday, March 16th, after market close. * The consensus EPS Estimate is -$0.34 [https://seekingalpha.com/symbol/CATX/e…
Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share.Per…
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today a…
Perspective Therapeutics, Inc. SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for c…
SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, tod…
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers thro…
Updated interim results from the Company’s [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight…
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring item…
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring item…
SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, tod…
Perspective Therapeutics, Inc. First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab [212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (…
Perspective Therapeutics, Inc. Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscape SEATTLE, Sept. 04, 2025 (GLOBE NEWS…
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announce…
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced…
PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX [https://www.chartmill.com/stock/quote/CATX/profile]) reported its second-quarter 2025 financial results, delivering revenue that significantly surpassed analyst expectations while posting a narr…
* Perspective Therapeutics press release [https://seekingalpha.com/pr/20199058-perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2025-results] (NYSE:CATX [https://seekingalpha.com/symbol/CATX]): Q2 GAAP EPS of -$0…
Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (OTCPK:TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Stratasys Ltd. (SSYS [https://seekingalpha.com/symbol/SSYS]) * Organigram Global (OGI [https:/…